The effect of Myrtoid suppository in hemerrhoid treatment

The comparative study of efficiency and safety of herbal anti hemorrhoid suppository of Myrtoid and conventional anti hemorrhoid suppository

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201506211165N7

Enrollment

100

Registered

2015-10-22

Start date

2015-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemorrhoids. Unspecified haemorrhoids without complication

Interventions

Intervention 1: Intervention group: Myrtoid anti hemorrhoid suppository, BID for two weeks. Intervention 2: Control group: conventional anti hemorrhoid suppository, BID for two weeks.

Treatment - Drugs

Intervention group: Myrtoid anti hemorrhoid suppository, BID for two weeks

Control group: conventional anti hemorrhoid suppository, BID for two weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All the visited patients with hemorrhoid symptoms who lack the exclusion criteria Exclusion criteria: External thrombosed hemorrhoid; Internal strangulated hemorrhoid; Anal fistula; Anal fissure; Anal abscess; Pregnancy; Portal hypertension; Type 3 and 4 hemorrhoids; Renal insufficiency; Malignancies

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bleeding. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Pain during bowel movements. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Constant pain in anus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Heaviness in anus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Tenesmus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Anal itching. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Irritation in anus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.	—

Measure

Time frame

Bleeding. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Pain during bowel movements. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Constant pain in anus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Heaviness in anus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Tenesmus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Anal itching. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.;Irritation in anus. Timepoint: Before intervention, 2 weeks after the initial intervention. Method of measurement: questionnaire.

—

Secondary

Measure	Time frame
Adverse effects. Timepoint: during the treatment period. Method of measurement: clinical assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahriar Payab

Baghiatallah University of Medical Sciences

sh.payab@yahoo.com+98 41 3444 0826

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026